Key Highlights
- Shares of Silo Pharma climbed 47.55% during after-hours trading on Monday, reaching $0.52
- European Patent Office delivered a Rule 71(3) notice indicating planned approval of the company’s PTSD prevention treatment patent
- Patent protection encompasses therapeutic methods utilizing serotonin 4 (5-HT4) receptor agonists for preventing stress-related fear and depression
- Columbia University holds the original patent with exclusive licensing granted to Silo Pharma, expected to provide protection throughout key European territories
- The company maintains approximately $4.98 million in market capitalization and trades significantly under its yearly peak of $1.18
Monday brought significant momentum to Silo Pharma as the European Patent Office (EPO) delivered a Rule 71(3) communication — an official indication of patent grant intent — for the company’s innovative preventative PTSD treatment approach.
The intellectual property filing, designated “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” centers on the serotonin 4 (5-HT4) receptor mechanism. This therapeutic strategy emphasizes preventing stress-triggered fear responses and depression-like symptoms proactively, distinguishing itself from conventional post-symptom treatments.
Columbia University serves as the original patent holder, with Silo Pharma securing exclusive licensing rights. The biotechnology firm is currently assessing Unitary Patent safeguards alongside individual country validations throughout Europe to maximize territorial reach.
Chief Executive Officer Eric Weisblum characterized the development as a “high-value milestone” that bolsters the organization’s worldwide intellectual property framework.
Patent Scope and Applications
The approved patent claims encompass therapeutic protocols for preventing stress-triggered fear responses, depression-related behaviors, and associated mood disorders through specific 5-HT4 receptor agonist compounds.
This represents a departure from conventional PTSD interventions that address symptoms following their emergence. Silo’s methodology concentrates on establishing stress resistance prophylactically.
The intellectual property directly underpins SPC-15, the organization’s primary PTSD development program. The company’s additional portfolio features SP-26 targeting fibromyalgia and chronic pain conditions, complemented by early-stage candidates addressing Alzheimer’s disease.
Market Performance Analysis
SILO concluded Monday’s standard trading session at $0.36 before surging to $0.52 during extended hours — representing a 47.55% increase.
The equity’s annual trading range provides broader context: shares touched $1.18 at their zenith and bottomed at $0.22 throughout the previous twelve months. This represents substantial volatility for an enterprise valued at approximately $5 million.
Benzinga’s equity analysis indicated SILO demonstrated downward price momentum across multiple timeframes prior to Monday’s announcement.
The after-market rally pushed shares beyond the $0.50 threshold for the first time in recent sessions, though the price remains well below the yearly maximum.
Following formal issuance, the EPO patent grant should provide Silo’s PTSD treatment with comprehensive protection throughout principal European commercial markets.
